Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
Date:2/15/2011

CRANBURY, N.J., Feb. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its second quarter ended December 31, 2010.  Palatin reported a net loss of $1.1 million, or $(0.09) per basic and diluted share, for the quarter ended December 31, 2010, compared to net income of $4.5 million, or $0.42 per basic and diluted share, for the same period in 2009.  

The net loss for the quarter ended December 31, 2010, compared to net income for the same period last fiscal year, was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca AB (AstraZeneca) as a result of the successful completion of the research collaboration portion of the agreements.

REVENUERevenues for the quarter ended December 31, 2010 were $1.0 million, consisting of $846,768 in grant revenue received under the Patient Protection and Affordable Care Act of 2010 and $195,408 in contract revenue pursuant to the collaboration agreement with AstraZeneca. For the quarter ended December 31, 2009, Palatin recognized $7.3 million of contract revenue under its collaboration agreement with AstraZeneca.

COSTS AND EXPENSESTotal operating expenses for the quarter ended December 31, 2010 were $2.9 million compared to $3.8 million for the comparable quarter of 2009.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels.

CASH POSITION / GOING CONCERNPalatin's cash, cash equivalents and investments were $3.7 million as of December 31, 2010, compar
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
2. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
3. Palatin Announces Strategic Realignment of Operations
4. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
6. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
8. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
9. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014   Epic Sciences, Inc. ("Epic"), ... diagnostics to personalize and advance the treatment and management ... T. Lucier as chairman of Epic,s board of ... Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board ... circulating rare cell analysis platform with special focus on ...
(Date:7/30/2014)... Connecticut Center for Advanced Technology, Inc. ... Hartford, Conn., was awarded a Rural Business Enterprise Grant ... that will determine the feasibility of implementing an ... Rural Development provided $53,000 for CCAT under the Rural ... of the feasibility study in fiscal year 2014. , ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The advanced ... the brain that are driving a revolution in the ... new peer-reviewed journal published by SPIE, the international ... issue coincides with the launch of the BRAIN Initiative ... articles that lay out a vision for and provide ...
Breaking Biology Technology:Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... Key words: somatostatin • ... SPA Imaging Beads , ... with a wide range of biological actions (1–3) and a reduction ... diseases. The SS analog, octreotide (SMS 201–995), is used clinically in ...
... , ... LEADseeker , , ... continually increase screening throughput. Yet accuracy and sensitivity remain vital concerns, ... System was developed to meet these demands by combining excellent detection ...
... into Gems of Knowledge Using discoveryHub™ , ... This paper discusses key problems and opportunities created by ... of life science data available today, and presents a ... rapid ‘harvesting’ and analysis of critical scientific data in ...
Cached Biology Technology:The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 5Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 2Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 3Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 2Exploiting the Life Science Data Explosion to Speed New Drug Discovery 3Exploiting the Life Science Data Explosion to Speed New Drug Discovery 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 5Exploiting the Life Science Data Explosion to Speed New Drug Discovery 6Exploiting the Life Science Data Explosion to Speed New Drug Discovery 7Exploiting the Life Science Data Explosion to Speed New Drug Discovery 8Exploiting the Life Science Data Explosion to Speed New Drug Discovery 9Exploiting the Life Science Data Explosion to Speed New Drug Discovery 10Exploiting the Life Science Data Explosion to Speed New Drug Discovery 11Exploiting the Life Science Data Explosion to Speed New Drug Discovery 12Exploiting the Life Science Data Explosion to Speed New Drug Discovery 13Exploiting the Life Science Data Explosion to Speed New Drug Discovery 14Exploiting the Life Science Data Explosion to Speed New Drug Discovery 15Exploiting the Life Science Data Explosion to Speed New Drug Discovery 16Exploiting the Life Science Data Explosion to Speed New Drug Discovery 17
(Date:7/30/2014)... A group of researchers from the University of Helsinki ... experimentally to reproduce in mice morphological changes which have ... gradual modifications in the embryonic development of mice teeth, ... morphologically are very similar to those observed in the ... millions of years ago. , To modify the ...
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... from HIV infection could be as simple as inserting ... , University of Washington bioengineers have discovered a potentially ... women from contracting HIV. Their method spins the drug ... with moisture, releasing higher doses of the drug than ... creams. , "This could offer women a potentially more ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... involving single gene mutations can reveal a great deal ... not accord with clinical expectations. Australian scientists acknowledge ... new study, which examines people with ,Autosomal Dominant Hyper ... mutation in the STAT3 gene. This makes patients slightly ...
... University of Minnesota have discovered that a human antiviral enzyme ... The discovery, reported in the July 14 issue of ... the enzyme, called APOBEC3B, is responsible for more than half ... Nature in February. APOBEC3B is part of a family ...
... key grassland species from taking hold and hampers efforts ... Work by scientists at Newcastle University, UK, has looked ... how this might inform future restoration work., Although renowned ... petunias or strawberry patch, still relatively little is known ...
Cached Biology News:Surprise finding reveals how adaptive our immune systems can be 2Antiviral enzyme contributes to several forms of cancer, University of Minnesota researchers say 2Grazing slugs hinder grassland restoration 2
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
... combines shaking and rocking for maximal fluid movement. ... mm stainless steel or acrylic platform, it is ... operation. The platform angle is easily adjusted from ... action and rotation speed of platform is adjusted ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: